Cover Image

13-valent Pneumococcal Conjugate Vaccine and Haemophilus Influenzae-Tetanus Toxoid Conjugate Vaccine in Patient with Systemic Juvenile Idiopathic Arthritis Receiving Tocilizumab: Clinical Case

Background. Vaccination coverage in patients with rheumatic diseases remains extremely low. Moreover, infections are the leading cause of death in such patients. Respiratory infections mortality is 2-5 times higher in adults with rheumatoid arthritis than in overall population. The most frequent inf...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ekaterina I. Alekseeva (Author), Dar'ya D. Van'kova (Author), Tatyana M. Dvoryakovskaya (Author), Kseniya B. Isaeva (Author), Rina V. Denisova (Author), Anna V. Mamutova (Author), Aleksandra M. Chomahidze (Author), Nikolay A. Mayanskiy (Author), Natalya E. Tkachenko (Author), Maria V. Kurdup (Author), Tatyana V. Radygina (Author), Irina V. Zubkova (Author)
Format:	Book
Published:	"Paediatrician" Publishers LLC, 2019-09-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study
by: Ekaterina I. Alexeeva, et al.
Published: (2020)

Pneumococcal Vaccine in Patients with Systemic Juvenile Idiopathic Arthritis Receiving Biologic Therapy: International Practice Review
by: Ekaterina I. Alekseeva, et al.
Published: (2019)

Experience of Vaccination of a Patient with Systemic Juvenile Idiopathic Arthritis (sJIA) with a 13-Valent Pneumococcal Conjugate Vaccine, prior to the Appointment of Therapy with Tocilizumab, an Anti-IL-6-Receptor Monoclonal Antibody
by: Daria D. Vankova, et al.
Published: (2018)

13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: V. K. Tatochenko, et al.
Published: (2012)

Recommendation for use of diphtheria and tetanus toxoids and acellular pertussis, inactivated poliovirus, Haemophilus influenzae type b conjugate, and hepatitis B vaccine in infants
by: Hye-Kyung Cho, et al.
Published: (2021)

The Experience of Vaccination of a Patient With Juvenile Idiopathic Arthritis With Frequent Respiratory Infections With a Pneumococcal 13-Valent Conjugate Vaccine During Methotrexate Therapy
by: Margarita A. Soloshenko, et al.
Published: (2017)

Impact of conjugate Haemophilus influenzae type b (Hib) vaccine introduction in South Africa
by: A von Gottberg, et al.
Published: (2006)

Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine
by: Beatriz Quiambao, et al.
Published: (2020)

PROGNOSTIC FACTORS FOR THE RESPONSE TO TOCILIZUMAB THERAPY IN PATIENTS WITH JUVENILE IDIOPATHIC ARTHRITIS WITHOUT SYSTEMIC MANIFESTATIONS: A COHORT STUDY
by: Ekaterina I. Alexeeva, et al.
Published: (2018)

Immunogenicity and safety of the Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine co-administered with human rotavirus, hepatitis A and 13-valent pneumococcal conjugate vaccines: results from a phase III, randomized, multicenter study in infants
by: Nicola P. Klein, et al.
Published: (2019)

Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine
by: C. Panpitpat, et al.
Published: (2000)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

RECOMMENDATION ON THE 7-VALENT PNEUMOCOCCAL CONJUGATED VACCINE AMONG CHILDREN
by: M.V. Fedoseenko, et al.
Published: (2009)

Pneumococcal conjugate 7-valent vacciPNEUMOCOCCAL CONJUGATE 7-VALENT VACCINE IN CHILDREN. REGIONAL EXPERIENCEne in children. Regional experience
by: N. L. Chernaya, et al.
Published: (2012)

PNEUMOCOCCAL INFECTION VACCINAL PREVENTION EFFICACY IN CHILDREN USING PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE
by: N. L. Chernaya, et al.
Published: (2013)

Antibody persistence up to 5 y after vaccination with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine in adolescents
by: Beatriz P. Quiambao, et al.
Published: (2017)

Safety profile of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV)
by: Sven Arne Silfverdal, et al.
Published: (2017)

Clinical Efficacy of Pneumococcal Conjugate 13-valent Vaccine in Young Children
by: S. M. Kharit, et al.
Published: (2016)

Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial
by: Markus Knuf, et al.
Published: (2022)

13-valent pneumococcal conjugate vaccine in Africa
by: Robert Cohen, et al.
Published: (2017)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

EXPERIENCE OF USE OF PNEUMOCOCCAL CONJUGATED 7-VALENT VACCINE IN SOME REGIONS OF RUSSIA
by: A.A. Ruleva, et al.
Published: (2010)

PHARMACOECONOMIC ASSESSMENT OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN IMMUNIZATION OF CHILDREN IN RUSSIAN FEDERATION
by: A. V. Rudakova, et al.
Published: (2014)

Health and economic outcomes of 20-valent pneumococcal conjugate vaccine compared to 15-valent pneumococcal conjugate vaccine strategies for adults in Greece
by: George Gourzoulidis, et al.
Published: (2023)

EXPERIENCE OF APPLICATION AND SAFETY ASSESSMENT OF THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN UNDER-5 CHILDREN
by: M. V. Fedoseenko, et al.
Published: (2014)

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine
by: James T. Peterson, et al.
Published: (2019)

Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate
by: Ekaterina Alexeeva, et al.
Published: (2019)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

INTERNATIONAL EXPERIENCE WITH 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
by: David G. McIntosh
Published: (2009)

A multi-centre, post-marketing surveillance study of Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar TCV®) in India
by: Raghu Reddy, et al.
Published: (2022)

Haemophilus influenzae type b and pneumococcal conjugate vaccination coverage in children aged 2-59 months in Malawi
by: Daphne Gadama, et al.
Published: (2021)

Otitis media outcomes of a combined 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine and 13-valent pneumococcal conjugate vaccine schedule at 1-2-4-6 months: PREVIX_COMBO, a 3-arm randomised controlled trial
by: Amanda Jane Leach, et al.
Published: (2021)

Cost-effectiveness of a national immunization program with the 13-valent pneumococcal conjugate vaccine compared with the 10-valent pneumococcal conjugate vaccine in South Korea
by: Hye-Young Kim, et al.
Published: (2021)

ERA OF CONJUGATE VACCINES: INTERNATIONAL EXPERIENCE OF SUCCESSFUL APPLICATION
by: M.V. Fedoseenko, et al.
Published: (2008)

ERA OF CONJUGATE VACCINES: INTERNATIONAL EXPERIENCE OF SUCCESSFUL APPLICATION
by: M.V. Fedoseenko, et al.
Published: (2008)

Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadministered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in toddlers<subtitle>A pooled analysis of randomized trials</subtitle>
by: Kristina A. Bryant, et al.
Published: (2012)

Antibody persistence to diphtheria toxoid, tetanus toxoid, Bordetella pertussis antigens, and Haemophilus influenzae type b following primary and first booster with pentavalent versus hexavalent vaccines
by: Nasamon Wanlapakorn, et al.
Published: (2024)

Estimation of 13-valent Pneumococcal Conjugate Vaccine Efficiency in Infants within National Immunization Schedule
by: Nikolay I. Briko, et al.
Published: (2019)

Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion
by: Silvia Ricci, et al.
Published: (2023)

Primary vaccination with the 10-valent pneumococcal non-typeable <it>Haemophilus influenzae </it>protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
by: Dicko Alassane, et al.
Published: (2011)